Small Interfering RNA (SiRNA) Market Size & Share, by Type (Liposome Based Systemic Therapy, Nanoparticle Based Systemic Therapy); End-user (Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions); Indication (Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5297
  • Published Date: Oct 09, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Small Interfering RNA Market size is expected to surpass USD 67 Billion by the end of 2036, witnessing around 18.5% CAGR during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of small interfering RNA was USD 13 Billion. The reason behind the growth is impelled by rising cases of cancer across the globe. Small interfering RNA has been studied as an effective treatment for cancer as it targets specific mRNA and blocks abnormal gene expression that causes the disease. By 2040, there will be more than 26 million new instances of cancer worldwide.

The growing partnerships and collaborations are believed to fuel the market growth. For instance, in 2022 Alnylam Pharmaceuticals and Novartis came together to treat liver disease by using siRNA to suppress a Novartis-discovered target, which could lead to the regeneration of functional liver cells and advance the possibility for new drugs in a variety of illness conditions.

Small Interfering RNA Market
Get more information on this report: Request Free Sample PDF

Small Interfering RNA Sector: Growth Drivers and Challenges

   Growth Drivers

  • Rising Popularity of Personalized Medicine – Small interfering RNA (siRNA) has emerged as a promising possibility for precision therapy in cancer and other diseases as it is highly specific and can be easily generated for multiple target genes.
  • Growing Geriatric Population- The elderly population is more susceptible to several age-related diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease which may benefit from SiRNA treatment.According to estimates, the proportion of the world's population over 60 years old is anticipated to treble from roughly 11 to more than 22% by 2050.


  • High Cost of Developing SiRNA Therapies - Despite their appealing method of action, small interfering RNA therapies confront several hurdles as they are often generated using chemical synthesis, which can be costly if large quantities are required.
  • Stringent Regulations to Obtain Approvals for SiRNA Therapies
  • Development of Effective Delivery Methods Can be Challenging

Small Interfering RNA Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 67 Billion

Forecast Year Market Size (2036)

~ USD 13 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Small Interfering RNA Segmentation

Type (Liposome Based Systemic Therapy, Nanoparticle Based Systemic Therapy)

The liposome based systemic therapy segment is estimated to account for 53% share of the global small interfering RNA market during the forecast period. Liposomes offer several advantages as a siRNA delivery system owing to their ability to improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells. Moreover, liposomes can selectively transport medications to the tumor, can be utilized to deliver specific medications to specific cell types to improve anti-tumor immune responses, and are known to be good carriers for drug delivery in conjunction with other therapies such as chemotherapy, radiation, and phototherapy.

Besides this, clinically proven liposomes are effective against pancreatic cancer as the only liposomal formulation currently licensed for the treatment of metastatic pancreatic cancer is nanoliposomal irinotecan (Onivyde) which was approved by the U.S. Food and Drug Administration (FDA) in 2022.

Indication (Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases)

SiRNA market from the oncology segment is set to garner a notable share of 39% shortly. SiRNA is one of the most essential therapeutic approaches for treating a variety of genetic disorders, including cancer since it has shown promise in the treatment of several malignancies, including breast and prostate cancer. To target cancer, siRNA can be supplied to the entire organism or to a specific tissue which will aid in reducing the expression of various multidrug-resistant genes in cancer cells.

End-User (Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions)

The research institutions segment is set to garner significant share of 44% during the forecast timeframe. SiRNA has recently been used in therapeutic applications and is now a potent method for studying gene function in research institutions that can be employed both in vitro and in vivo.  Moreover, their use aids in the development of novel techniques to reduce off-target effects brought on by detrimental protein binding or unwanted targeting of mRNA in addition to assist researchers in better understanding the process of gene silence.

Our in-depth analysis of the global market includes the following segments:


  • Liposome Based Systemic Therapy
  • Nanoparticle Based Systemic Therapy


  • Hospital
  • Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions


  • Cardiovascular Diseases
  • Respiratory Diseases
  • Oncology
  • Neurodegenerative Diseases
  • Infectious Diseases

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Small Interfering RNA Industry - Regional Synopsis

North American Market Forecast

Small Interfering RNA market in North America is predicted to account for the largest share of 37% by 2036 impelled by the increasing spending in healthcare. This has led to the development of efficient and effective therapies for small interfering RNA in the region. Besides this, as a consequence, many academic institutions including Harvard University and the University of California, San Francisco (UCSF) have started researching small interfering RNA. For instance, at the UNIVERSITY OF CALIFORNIA, RIVERSIDE two scientists Shou-wei Ding and Shabihah Shahrudin identified in a recent research that a novel Dicer enzyme isoform a protein that functions similarly to another protein, protects mouse and for human stem cell treatment from RNA viruses which could significantly enhance siRNA therapeutics to treat SARS-CoV-2. According to estimates, in 2021, healthcare spending in the United States increased by more than 2% to roughly USD 4 trillion.

APAC Market Statistics

The APAC Small Interfering RNA market is estimated to be the second largest, during the forecast timeframe led by growing advancements in biotechnology. In recent years, India's biotechnology industry has risen quickly owing to increased economic prosperity and health consciousness, which has led to significant progress in the development of siRNA therapies for the treatment of a variety of disease targets, including viral infections and cancer.

Research Nester
Small Interfering RNA Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Small Interfering RNA Landscape

    • GE
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Scientific
    • Arbutus Biopharma
    •  Sanofi Genzyme
    •  Sylentis
    •  Arrowhead Research
    •  Genecon Biotechnologies
    •  Silent Therapeutics
    •  Horizon Discovery
    •  OPKO Health
    • Agios Pharmaceuticals, Inc.
    • Novartis

In the News

  • Agios Pharmaceuticals, Inc. partnered with Alnylam Pharmaceuticals, Inc. announced to develop and commercialize Alnylam's innovative preclinical siRNA targeting TMPRSS6, for patients with polycythemia vera (PV), a rare hematologic condition. Furthermore, the company aims to provide a simple, disease-modifying therapy option that targets the underlying pathophysiology of PV and to provide a breakthrough therapy option for this patient community with significant unmet needs.
  • Novartis received approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran) a small interfering RNA (siRNA) therapy a new strategy to lower low-density lipoprotein cholesterol also known as bad cholesterol in the bloodstream by increasing the liver's natural ability to suppress the creation of a protein that contributes to high circulating cholesterol levels to assist those who have difficulty sticking to self-administered medications with higher dose frequency.

Author Credits:  Radhika Pawar

  • Report ID: 5297
  • Published Date: Oct 09, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of cancer across the globe and the growing partnerships and collaborations are the major factors driving the growth of the market.

The market size of small interfering RNA is anticipated to attain a CAGR of 18.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, AInylam Pharmaceuticals, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health

The liposome based systemic therapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Small Interfering RNA Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying